drugset / Trial / NCT02857777

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects

NCT02857777

Phase 1 Completed 37 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in elderly Japanese subjects and healthy younger adult Japanese subjects.

Timeline

Start
2016-08-09
Primary completion
2017-01-27
Completion
2017-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 28 mg Intranasal
Subject Esketamine Other / unclassified 56 mg Intranasal
Subject Esketamine Other / unclassified 84 mg Intranasal

Indications

No indication recorded.